Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 16;8(1):27.
doi: 10.3390/antibiotics8010027.

A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia

Affiliations
Free PMC article
Review

A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia

Mark Biagi et al. Antibiotics (Basel). .
Free PMC article

Abstract

Despite advancements in therapy, pneumonia remains the leading cause of death due to infectious diseases. Novel treatment strategies are desperately needed to optimize the antimicrobial therapy of patients suffering from this disease. One such strategy that has recently garnered significant attention is the use of inhaled antibiotics to rapidly achieve therapeutic concentrations directly at the site of infection. In particular, there is significant interest in the role of inhaled polymyxins for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, due to their retained activity against multi-drug resistant Gram-negative pathogens, including Acinetobacter baumannii and Pseudomonas aeruginosa. This review will provide a comprehensive overview of the pharmacokinetic/pharmacodynamic profile, clinical outcomes, safety, and potential role of inhaled polymyxins in clinical practice.

Keywords: HAP; VAP; colistin; inhaled antibiotics; pneumonia; polymyxin.

Conflict of interest statement

E.W. serves on the speaker’s bureau for Melinta Therapeutics, Astellas Pharma, and Achaogen and on the advisory board for Shionogi. All other authors certify no potential conflicts of interest.

Figures

Figure 1
Figure 1
CMS (top panels) and colistin (bottom panels) concentrations in ELF (open squares) and plasma (filled triangles) following a single dose via aerosol or IV administration at steady state. Reprinted with permission from Boisson et al [35].

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Heron M. Deaths: Leading Causes for 2016. Natl. Vital Stat. Rep. 2018;67:1–77. - PubMed
    1. Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States. [(accessed on 1 January 2019)];2013 Available online: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
    1. Sopena N., Heras E., Casas I., Bechini J., Guasch I., Pedro-Botet M.L., Roure S., Sabria M. Risk factors for hospital-acquired pneumonia outside the intensive care unit: A case-control study. Am. J. Infect. Control. 2014;42:38–42. doi: 10.1016/j.ajic.2013.06.021. - DOI - PubMed
    1. Micek S.T., Chew B., Hampton N., Kollef M.H. A Case-Control Study Assessing the Impact of Nonventilated Hospital-Acquired Pneumonia on Patient Outcomes. Chest. 2016;150:1008–1014. doi: 10.1016/j.chest.2016.04.009. - DOI - PMC - PubMed
    1. Magill S.S., Edwards J.R., Bamberg W., Beldavs Z.G., Dumyati G., Kainer M.A., Lynfield R., Maloney M., McAllister-Hollod L., Nadle J., et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 2014;370:1198–1208. doi: 10.1056/NEJMoa1306801. - DOI - PMC - PubMed
Feedback